Data from a 6-year analysis of the APHINITY trial showed that adding pertuzumab to the previous standard of trastuzumab plus chemotherapy after surgery continued to reduce the risk of recurrence and death in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. There were fewer deaths in patients treated with pertuzumab, although the survival benefit was not statistically significant at this time.
In its primary analysis, the APHINITY trial demonstrated that pertuzumab when added to adjuvant trastuzumab and chemotherapy statistically significantly (although modestly) improved invasive disease-free survival (iDFS) among patients with HER2-positive, operable breast cancer . Between November 2011 and August 2013, a total of 2,400 patients were randomly assigned to receive pertuzumab whilst 2,404 patients received placebo . The median follow-up was 45.4 months. In the intention-to-treat (ITT) population, the estimates of the...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« High rates of ROR-low disease with chemotherapy-free regimen in HR+/HER2- patients Next Article
S-1 shows promising results in combination with endocrine therapy »
Table of Contents: SABCS 2019
Screening, Detection, and Diagnosis
Phase 2 Trial Update
Phase 3 Trial Update
Long-Term Study Results
Triple-Negative Breast Cancer
HER2-Positive Breast Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.